Early Detection in Brazil Is a Game Changer for Lung Cancer Care

PRINCETON, NJ / ACCESS Newswire / June 5, 2026 / Bristol-Myers Squibb Company


Originally published on Devex.com

In a special edition of the This Week in Global Development podcast, Devex cofounder and Executive Vice President Alan Robbins sits down with Brazilian thoracic surgeon Dr. Ricardo Sales do Santos to discuss a revolutionary approach to tackling lung cancer in medically underserved communities in Brazil.

As the most lethal form of cancer globally, lung cancer often goes undetected until its final stages, but Dr. Santos and the Bristol Myers Squibb Foundation are working to change that narrative through a combination of mobile technology and local capacity building. By bringing advanced CT scanning units directly into high-risk, low-income communities, they are catching tumors when they are small and potentially curable, fundamentally shifting the odds for thousands of patients.

The conversation also touches on the logistical and cultural hurdles of delivering specialized oncology care to remote areas. Dr. Santos highlights the importance of "bringing the clinic to the patient," utilizing mobile CT units and telemedicine to bridge the gap in healthcare access. Beyond the technology, the success of the program relies heavily on empowering local health workers and community members to recognize early cancer warning signs and overcome the stigma associated with a cancer diagnosis. This approach not only improves individual health outcomes but also strengthens the broader healthcare system, offering a scalable model for global health initiatives.

View the conversation here: Special edition: Early detection in Brazil is a game changer for lung cancer care

Find more stories and multimedia from Bristol-Myers Squibb Company at 3blmedia.com.

Contact Info:

Spokesperson: Bristol-Myers Squibb Company
Website: https://www.3blmedia.com/profiles/bristol-myers-squibb-company
Email: info@3blmedia.com

SOURCE: Bristol-Myers Squibb Company



View the original press release on ACCESS Newswire

News Provided by ACCESS Newswire via QuoteMedia

BMY
The Conversation (0)
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retirement Income Security Act of 1974

Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retirement Income Security Act of 1974

Lawsuits have been filed alleging that a number of large corporate employers have offloaded billions of dollars in pension obligations to Athene Annuity and Life Company andor Athene Annuity & Life Assurance Company of New York, subsidiaries of Athene Holding Ltd. (collectively, "Athene") in... Keep Reading...
Bristol Myers Squibb Reports First Quarter Financial Results for 2023

Bristol Myers Squibb Reports First Quarter Financial Results for 2023

Reports First Quarter Revenues of $11.3 Billion Posts First Quarter GAAP Earnings Per Share of $1.07 and Non-GAAP EPS of $2.05; Includes Net Impact of ($0.01) Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income Delivers Strong Revenue Growth of 8% from In-Line... Keep Reading...
Bristol Myers Squibb Announces Leadership Transition Plan

Bristol Myers Squibb Announces Leadership Transition Plan

Giovanni Caforio, MD, Bristol Myers Squibb Chairman and CEO, to Retire as CEO, Effective November 1, 2023; Will Continue as Executive Chairman of the Board Christopher Boerner, PhD, EVP, Chief Commercialization Officer, Appointed EVP, Chief Operating Officer, Effective Immediately; to Succeed... Keep Reading...
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS®  for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy

If approved, CAMZYOS would be the first cardiac myosin inhibitor in Europe that specifically targets the source of obstructive HCM Recommendation based on positive Phase 3 EXPLORER-HCM and VALOR-HCM trials demonstrating benefit in patients receiving CAMZYOS versus placebo Bristol Myers Squibb... Keep Reading...
Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production

Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production

Libertyville, Illinois facility bolsters long-term viral vector supply with multi-product, in-house viral vector production capabilities Bristol Myers Squibb (NYSE: BMY) today announced expansion of its global cell therapy manufacturing network to enable in-house viral vector production through... Keep Reading...

Interactive Chart

Latest Press Releases

Related News